World-Class Science in a World-Class Setting

Total Page:16

File Type:pdf, Size:1020Kb

World-Class Science in a World-Class Setting World-class science in a world-class setting Contents “ With our partners and Introducing Alderley Park 4 A world-class setting for world-class science 6 the community of At the heart of a scientific ecosystem 8 A clear vision for the future 10 exceptional scientists Mereside 12 The Radnor Atrium 13 Alderley Park laboratory space 14 who choose to remain Laboratory areas and facilities 16 The BioHub Incubator 20 Parklands 21 at Alderley Park, we Our first major redevelopment 22 The conference centre 24 A well-connected location 26 will build a flagship for A great place to live and work 28 A historic, natural setting for health and wellbeing 30 a vibrant life sciences industry in the North of England.” Chris Oglesby MSP Chairman and Bruntwood CEO P. 2 P. 3 Introducing Alderley Park Alderley Park represents a once-in-a-generation opportunity for the UK life science sector. Until March 2014, Alderley Park was the global R&D HQ for AstraZeneca, with a long and distinguished track record for drug discovery and development. As AstraZeneca prepare to relocate most of their operations, they leave two remarkable legacies and a huge opportunity. The first is an exceptional talent pool of science professionals who have elected to remain in our region, and who want to continue their work at Alderley Park. The second is an extraordinarily well-invested campus of beautiful buildings, superbly equipped for full spectrum bioscience, located in a tranquil lakeside setting. Alderley Park is a major asset within the UK’s life science industry, with an international reputation. As owners of the site, Manchester Science Partnerships’ (MSP) intention is to maintain and strengthen this position, working with health science partners across the North of England and beyond, and most importantly with the business community. Our goal is to create within this remarkable site, a collaborative community of bioscience innovators and businesses at every stage of growth, with access to superb specialist equipment and a full range of support services in an open innovation campus environment. As part of the Bruntwood Group, it is our way to be outward facing and to play a full part in the wider life of the communities we serve. At Alderley Park we will fulfil our vision by working with our commercial, academic and clinical partners, and with national policy makers to ensure that the work which is done here is of global quality and impact. Alderley Park is uniquely placed to drive the future growth of this critically important sector for the economy and society. We are confident that with our partners we will realise that opportunity in full. Rowena Burns Chief Executive Manchester Science The Radnor reception Partnerships P. 4 P. 5 A world-class 400 1.5 550 50 Size (acres) of the Million lettable Million pounds Years established as Alderley Park estate sq ft under MSP invested in the site UK centre of R&D setting for development plans over the last decade excellence world-class science With over 1.5m sq ft of premier scientific, laboratory, office and conferencing space, Alderley Park is the leading life science facility in the North of England and the largest R&D campus of its kind in the UK. Set within 400 acres of beautiful Cheshire Alderley Park is centrally located in the UK and is parkland, the campus has been an internationally very well connected for such an idyllic parkland important scientific location for over 50 years, with setting, boasting exceptional transport links. Located a rich heritage in pharmaceutical R&D and drug just five miles from Manchester Airport and 12 miles development. It has been home to the development from Manchester city centre, it is at the heart of of 12 new drugs, and ground-breaking discoveries the North West motorway network, providing easy such as beta blockers through the work of Nobel access by car across the whole of the UK. With two prize-winning physician and pharmacologist, Sir mainline rail stations within 20 minutes of the site, James Black, and more recently a number of London is less than two hours away by train. targeted therapies in oncology. Millions of patients have benefited from innovations developed at Alderley Park and it is the most commercially What Alderley Park offers: successful drug development site of its kind in the • Important scientific assets world. • High-specification office space With over £550m invested by AstraZeneca in world-class facilities and infrastructure over the past • Industry-leading laboratory space decade, Alderley Park is one of the best-invested bioscience R&D sites in Europe. Its nationally- • An international conference centre, restaurants significant assets include not only highly-specialised and cafés labs, offices and equipment, but also some of • Gym and indoor and outdoor sports facilities the worlds most skilled and experienced science professionals. With its environment, energy and • 200 acres of private parkland power infrastructure all purposely-designed for a specialist Life Science facility, Alderley Park is unique • Living and hotel accommodation close by, with both in its quality and scale. future on-site accommodation planned P. 6 P. 7 At the heart of a scientific The University of Access is available to There are 152,000 Manchester has the regional £42m engineering and largest number of Life Science science students ecosystem international students Investment Funds within a one hour drive in the UK The Manchester Alderley Park is at the centre of a growing scientific ecosystem Academic Health The region has in the North of England and is the primary focus for the regions Science Centre includes The Northern Health one of the highest Europe’s largest Science Alliance bioscience business cluster, driving the development of the next recruiting NIHR cancer research and covers a 15m generation of life science companies through collaboration with Clinical Research delivery centre and patient population academic and clinical partners. Networks Europe’s largest With Manchester just 30 minutes away, Throughout the region, MSP has close links childrens hospital the vast wealth of the city’s assets, activity with the leading NHS trusts and research and reputation as a hotspot of scientific intensive universities through the Northern discovery and innovation provides significant Health Science Alliance and with other opportunities for companies and R&D centres business clusters and innovation communities located at the Park. MSP’s Corridor sites are through the North West Innovation Network. home to significant clusters across digital, MSP is the largest science park operator in the medtech, healthcare technologies, advanced UK with a 30 year track record in catalysing the materials and manufacturing. Manchester’s growth of science and technology businesses. universities offer multiple opportunities to Through a trusted network of scientists, connect with world-leading academics and innovators, entrepreneurs and investors, MSP research centres in specialist areas including provides the right connections for innovation to e-health, oncology and genetics. flourish and concepts to become commercial Thirty five miles in the opposite direction lies reality. MSP’s partnership structure is at the the port city of Liverpool, boasting the UK’s heart of its culture and approach to creating largest concentration of biopharmaceutical the right places and conditions for science manufacturing facilities in the UK. In and technology businesses to thrive. By Macclesfield, just a few miles from Alderley locating at Alderley Park, businesses can take Park, is AstraZeneca’s second largest advantage of these established networks, manufacturing and late-stage R&D site which scientific talent and pipeline of innovation that employs 2,300 staff from where pharmaceutical runs from academia through clinical research products are shipped globally on a daily basis. to commercial development and business success. P. 8 P. 9 NETHER ALDERLEY RADNOR MERE ACCESS POINT A clear vision for the future AD ON RO ONGLET C MSP’s goal at Alderley Park is to create a vibrant and diverse bioscience community in an open innovation environment that will become a flagship location for life science sector growth. As Alderley Park’s new owners, MSP is What the future offers: Following the acquisition of Alderley developing a long-term masterplan that Park by MSP, AstraZeneca is gradually • A collaborative and connected aims to create a dynamic community of decanting its R&D activity to a new site commercial community R&D centres and science and technology in an agreed programme to 2017. Some of 5000+ people companies working in an environment areas of the site are immediately available designed to encourage collaboration • Approximately 1.5m+ sq ft of for new occupiers, with other individual and the sharing of risk and reward that scientific and commercial space buildings and facilities gradually is essential for the delivery of future transferring to MSP on AstraZeneca’s investment and business success. • Long-term capital investment departure. As the business departs, it programme with £30m for will leave behind a range of top quality, Significant investment and an extensive the first phase to 2018 specialist scientific facilities as well as transformation programme will see a range of well-appointed and highly • Access to £42m Life Science MSP redevelop and expand the site desirable research and office spaces. into a globally leading campus for Investment Fund the next generation of life science The following
Recommended publications
  • Alderley Park the Future As a World-Class Life Science Facility Planning Application Summary Document
    DECEMBER 2015 ALDERLEY PARK THE FUTURE AS A WORLD-CLASS LIFE SCIENCE FACILITY PLANNING APPLICATION SUMMARY DOCUMENT Alderley Park is a world-class Life Science research and development (R&D) facility. The site currently houses around 190,000 sq m of premier scientific laboratory space, offices, restaurants, cafes, conferencing space and energy plant, set in 400 acres of parkland. As a centre for scientific research, it is one of the few facilities in the country with a comprehensive offering to support drug discovery and development. It was AstraZeneca’s global lead centre for cancer research, employing at its peak up to 10,000 people in highly skilled jobs. These facilities at Alderley Park are high-quality A planning application has been submitted to and high-tech, and require significant ongoing Cheshire East Council for future development investment to retain them. £550 million has been at Alderley Park. The planning application invested in Alderley Park since 1997 and further, has been allocated the reference number major investment is required to repurpose the site 15/5401M. from single to multi-occupier use, maintain the facilities and cover ongoing overheads. This summary document sets out the key elements of the proposals. ILLUSTRATIVE MASTERPLAN SIGNIFICANT INVESTMENT PROPOSED OVER THE NEXT 10 YEARS In March 2013, AstraZeneca announced The site was purchased by Bruntwood/MSP, its decision to relocate its R&D facilities to part of Alderley Park Ltd who now wish to Cambridge, leading to uncertainty over the secure the future of the site, retaining talent and future of Alderley Park and its role in the local jobs, by taking forward the Taskforce’s vision.
    [Show full text]
  • Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting
    Author Manuscript Published OnlineFirst on December 16, 2013; DOI: 10.1158/1535-7163.MCT-13-0420 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Fully Human Anti-Hedgehog Antibodies Novel neutralizing hedgehog antibody MEDI-5304 exhibits antitumor activity by inhibiting paracrine hedgehog signaling. Authors: Neil R. Michaud1*, Youzhen Wang1, Kristen McEachern1, Jerold J. Jordan1, Anne Marie Mazzola1, Axel Hernandez1, Sanjoo Jalla2, Jon W. Chesebrough2, Mark J. Hynes3, Matthew Belmonte 1, Lidong Wang3, Jaspal S. Kang4#, Jelena Jovanović5, Naomi Laing1, David W. Jenkins1, Elaine Hurt2, Meina Liang6, Christopher Frantz7, Robert E. Hollingsworth2, Diane M. Simeone3, David C. Blakey8, and Vahe Bedian1* Authors’ affiliation: 1Oncology iMED, AstraZeneca-R&D Boston, Waltham, MA 2Oncology Research, MedImmune LLC, Gaithersburg, MD 3Translational Oncology Program, University of Michigan, Ann Arbor, MI; 4Amgen British Columbia, Burnaby, BC, Canada 5Lead Generation- Research, Medimmune LLC, Granta Park, Cambridge, UK 6Clinical Pharmacology and DMPK, MedImmune LLC, Hayward, CA 7Biologics Safety Assessment, MedImmune LLC, Mountain View, CA 8Oncology iMed, AstraZeneca, Alderley Park, Macclesfield. UK #Current address: Paul Kang, CSO, Innovative Targeting Solutions Inc., Burnaby BC, Canada *corresponding authors: Neil R. Michaud, Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 e-mail: [email protected] Vahe Bedian Ph.D. Oncology iMED AstraZeneca-R&D Boston Waltham, MA 02451 phone:781-839-4613 e-mail: [email protected] Running title: Fully Human Anti-Hedgehog Antibodies Key Words: Hedgehog, Antibody, Xenograft, XenoMouse, cancer stem cells Grant Support: This work was funded by AstraZeneca PLC and MedImmune LLC. Disclosure of Potential Conflicts of Interest: There are no potential conflicts of interest.
    [Show full text]
  • 6Th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25Th - 26Th Sept 2014
    6th Annual Translational Medicine Conference ‘Personalising Health and Care’ Date: 25th and 26th September 2014 | Venue: City Hotel, Derry/Londonderry, N.Ireland, UK 1 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Conference Sponsors 2 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 Contents Page Conference Programme .................................................................................... 4 Biographies .......................................................................................................... 6 - 9 Delegate List ........................................................................................................ 10 - 12 Bio-Entrepreneur Programme........................................................................ 13 About C-TRIC ....................................................................................................... 14 - 15 Abstracts Poster Presentations................................................................. 16 - 42 Abstracts Oral Presentations................................................................. 43 Abstracts Poster List................................................................. 44 3 6th Annual Translational Medicine Conference City Hotel, Derry/Londonderry, Northern Ireland 25th - 26th Sept 2014 ‘Personalising Health and Care’ - Conference Programme Day One Thursday 25th Sept 1:00 pm Registration and Tea/Coffee 4.30 pm Oral
    [Show full text]
  • Alderley Park Development Framework
    Alderley Park Development Framework Consultation Draft - January 2015 0i 2 Contents 1 Introduction 2 The Site 3 Planning Policy 4 Design Guidance 5 Indicative Masterplan 6 Planning Applications 7 Summary and Next Steps Appendices 3 1 Introduction Alderley Park, a research and development site The Taskforce commissioned a study to establish the new vision for the site. It allocates Alderley Park as an renowned for the discovery and development of potential future demand from the life science sector, for ‘opportunity site’, seeking to promote and encourage the innovative new medicines, is a key part of the North the world class laboratory and office space on site1. That development of the Life Science Park whilst recognising West Life Science Ecosystem. Opening more than 40 study indicated that whilst there would not by any means that there is likely to be a need for a degree of flexibility years ago, the site has a rich heritage of important be an instant demand for all the site’s facilities, with an regarding land uses to deliver, grow and sustain the Life advancements in medical treatments, including a appropriate business model, there is potential to build on Science Park vision. number of anti-cancer treatments. As the lead centre the BioHub concept, repurposing the site to offer facilities Until the adoption of the CELPS, the current development for cancer research, Alderley Park currently houses which complement existing life science resources across plan for the area remains the Macclesfield Borough the global Advanced Lead Discovery Centre, and its the region, such that Alderley Park can continue to be a Local Plan.
    [Show full text]
  • Directions to Alderley Park Conference Centre
    Directions to Alderley Park Conference Centre Travel by rail Travel by road Travel by air A regular shuttle service from Alderley Alderley Park is centrally located on Alderley Park is located within 20 minutes Park provides convenient transfer from both the UK’s North/South and East/ drive time on uncongested roads to nearby Wilmslow and Macclesfield mainline West motorway network. The main M6 Manchester Airport, which serves more stations, connecting with direct services motorway is just 20 minutes’ drive away destinations than any other airport in to London that run every 20 minutes and on uncongested roads. Manchester city the UK. This top 20 international airport take under two hours. Manchester is a key centre can be accessed in 40 minutes and handles over 22m passengers every year rail hub on the West Coast mainline linking Liverpool and Leeds can be reached within to over 220 worldwide destinations allowing London with Scotland as well as being the one hours’ drive time, with Birmingham comprehensive direct flight access to main arterial rail link between England, two hours drive time from site. On-site car Europe, the US and the Far East. In addition Wales and Scotland. parks at Alderley Park can accommodate Liverpool airport is 40 miles away and approximately 4,000 vehicles. Birmingham West Midlands is 71 miles away. Regional map Local map TO MANCHESTER AIRPORT M6 to Preston, M62 to Leeds MANCHESTER Carlisle, Scotland ROAD 4 3 A34 - TO M66 A M6 Rochdale M60 J3 & MANCHESTER Heywood Bury M62 W A T E R L A Bolton N E 8 WILMSLOW
    [Show full text]
  • Large-Scale Isolation of Human Skeletal Muscle Satellite Cells from Post-Mortem Tissue and Development of Quantitative Assays to Evaluate Modulators of Myogenesis
    J Cachexia Sarcopenia Muscle (2013) 4:157–169 DOI 10.1007/s13539-012-0097-z ORIGINAL ARTICLE Large-scale isolation of human skeletal muscle satellite cells from post-mortem tissue and development of quantitative assays to evaluate modulators of myogenesis Ian C. Scott & Wendy Tomlinson & Andrew Walding & Beverley Isherwood & Iain G. Dougall Received: 24 July 2012 /Accepted: 25 November 2012 /Published online: 24 January 2013 # Springer-Verlag Berlin Heidelberg 2013 Abstract Methods Satellite cells were isolated by digestion of post- Background During aging, there is a decreased ability to mortem skeletal muscle and selection using anti-CD56 maintain skeletal muscle mass and function (sarcopenia). MicroBeads. CD56+ cell-derived myotubes were quantified Such changes in skeletal muscle are also co-morbidities by high content imaging of myosin heavy chains. TaqMan- of diseases including cancer, congestive heart failure polymerase chain reaction arrays were used to quantify expres- and chronic obstructive pulmonary disease. The loss of sion of 41 selected genes during differentiation. The muscle mass results in decreased strength and exercise effects of activin receptor agonists and tumour necrosis tolerance and reduced ability to perform daily activities. factor alpha (TNFα) on myogenesis and gene expres- Pharmacological agents addressing these pathologies sion were characterised. could have significant clinical impact, but their identifi- Results Large-scale isolation of CD56+ cells enabled devel- cation requires understanding of mechanisms driving opment of a quantitative myogenesis assay with maximal myotube formation (myogenesis) and atrophy and pro- myotube formation 3 days after initiating differentiation. vision of relevant assays. The aim of this study was to Gene expression analysis demonstrated expression of 19 develop robust in vitro methods to study human genes changed substantially during myogenesis.
    [Show full text]
  • Cardiovascular Safety Risk Assessment for New Candidate Drugs from Functional and Pathological Data
    Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data 14th & 15th November 2013 Alderley Park Conference Centre, Cheshire, UK The 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data th th 14 & 15 November 2013, Alderley Park Conference Centre, UK 28th ANNUAL SCIENTIFIC MEETING of the BRITISH SOCIETY OF TOXICOLOGICAL PATHOLOGY held jointly with the SAFETY PHARMACOLOGY SOCIETY I am delighted to welcome you to the 28th annual meeting of the British Society of Toxicological Pathology (BSTP) held jointly with the Safety Pharmacology Society (SPS) and sponsored by the Health and Environmental Sciences Institute (HESI) at The Alderley Park Conference Centre, Cheshire, UK on 14th and 15th November 2013. The excellent programme on offer at this meeting is a tribute to the work of many people, including the BSTP Council and Education Sub-Committee. However, I would particularly like to thank the Scientific Organisers, Stephanie Klein and Will Redfern, for their ideas and energy in successfully combining morphologic and functional aspects of cardiovascular toxicology. This was the aspiration of the meeting and I think it has been fulfilled. We know that much scientific progress is made at the intersection of different disciplines, and the BSTP is keen to establish fruitful collaborations with many other societies. This results in meetings of wider interest and allows for hot topics at the edge of our current understanding to be discussed. This meeting, organised with Jean-Pierre Valentin of the SPS, very much exemplifies this approach and I hope it forms the template of many more to come.
    [Show full text]
  • Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected]
    The Royal Society of Biology Register of Eligible Qualified Persons – Web Version Copyright © 2013 The Royal Society of Biology All rights reserved No part of this register may be reproduced, copied or transmitted in any form or by any means without written permission from the Royal Society of Biology Anyone wishing to use details from the Register must contact the Professional Registers Programme Manager BAKER, C CBiol MRSB QualiPharm Consultancy Ltd Tel: 07968 266691 Email: [email protected] Website: www.qualipharm.co.uk Registered 2007 BARNARD DD, CBiol Holly Lodge LLantilio Crossenny Monmouthshire NP7 8TF Registered 1992 BERLANGA H, CBiol MRSB Allergy Therapeutics plc Dominion Way | Worthing West Sussex BN14 8SA Tel: 01903 844 703 Email: [email protected] Website: www.allergytherapeutics.com Registered 2011 BIRCH I, CBiol MRSB BECO Integrated Services Ltd Email: [email protected] Charles Darwin House, 12 Roger St, London WC1N 2JU Tel: +44 (0)20 7685 2550 [email protected] www.rsb.org.uk Registered Charity No.277981 Incorporated by Royal Charter Registered 2010 BURROWS M, MRSB Shire Pharmaceuticals Ireland Ltd Miesian Plaza 50 -58 Lower Baggot Street Dublin DO2 Y754 Tel: 0877112159 Email: [email protected] Registered 2015 CALLAGHAN M, MRSB Piramal Pharma Solutions Email: [email protected] CHESTERTON NJ, MRSB Dolby Vivisol Unit 18 Arkwright Road Bedford Bedfordshire MK42 0LQ Tel: 07584 086330 Email: [email protected] Registered 2011 CLACK S, CBiol MRSB Quaph Consulting
    [Show full text]
  • Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report
    Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Final Report Commercial in Confidence 29 January 2014 Impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 1: Economic Impact Assessment Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 4 3. Research Method & Impact Parameters .......................................................................... 13 4. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘pre-disinvestment ’ ................................................................................................................................................. 22 5. The Quantitative Contribution of AstraZeneca at Alderley Park – ‘post-disinvestment ’ ................................................................................................................................................. 33 6. The Wider Qualitative effects of disinvestment .............................................................. 37 7. Perspectives on the Spatial Effects and Consequences of Disinvestment ................. 43 8. Conclusions & Recommendations ..................................................................................
    [Show full text]
  • The Impact of the Disinvestment by Astrazeneca at Alderley Park, Cheshire Final Report Contents
    The i mpact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Volume 2: Future Market Demand Assessment Final Report Commercial in Confidence 11 February 2014 The impact of the disinvestment by AstraZeneca at Alderley Park, Cheshire Final Report Contents Executive Summary .................................................................................................................. i 1. Introduction .......................................................................................................................... 1 2. Setting the Scene ................................................................................................................. 5 3. Thinking & Planning for Demand ..................................................................................... 30 4. Projection 1 – An Initial Perspective on Demand ........................................................... 43 5. Qualitative Perspectives on Demand – the General View ............................................. 53 6. Qualitative Perspectives on Demand – the particular case of HE and Research Institutes ................................................................................................................................. 72 7. Projection 2 - A Revised Perspective on Demand .......................................................... 78 8. The Story of Existing and Pipeline Supply ...................................................................... 81 9. A Forward View of Economic Impact ..............................................................................
    [Show full text]
  • 022405Orig1s000
    CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 022405Orig1s000 PHARMACOLOGY REVIEW(S) MEMORANDUM Vandetanib Date: March 25, 2011 To: File for NDA 22405 From: John K. Leighton, PhD, DABT Associate Director for Pharmacology/Toxicology Office of Oncology Drug Products I have examined pharmacology/toxicology supporting review and labeling provided by Drs. Gehrke and Dorsam and supervisory memorandum provided by Dr. Verbois. I concur with their conclusions that vandetanib may be approved for the proposed indication with the carcinogenicity studies to be provided as described in the Action Letter. Reference ID: 2923639 --------------------------------------------------------------------------------------------------------- This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature. --------------------------------------------------------------------------------------------------------- /s/ ---------------------------------------------------- JOHN K LEIGHTON 03/25/2011 Reference ID: 2923639 MEMORANDUM Date: March 25, 2011 From: S. Leigh Verbois, Ph.D. Supervisory Pharmacologist Division of Drug Oncology Products To: File for NDA #022405 Vandetinib Re: Approvability of Pharmacology and Toxicology Non-clinical studies that investigated the pharmacology and toxicology of vandetinib provided to support NDA 022405 for the treatment of patients with unresectable locally advanced or metastatic medullary thyroid cancer were reviewed in detail by Brenda Gehrke,
    [Show full text]
  • Site Selection Final Report: Alderley Park
    Cheshire East Local Plan Site Selection Final Report: Alderley Park July 2016 Contents 1 Introduction 1 2 Sustainability Appraisal 2 3 Neighbourhood Plan 2 4 Sites Assessed and Recommendation 2 Site PSS1200 2 5 Overall Conclusion (Stage 9) 6 Appendices Appendix 1: Site Map 7 Appendix 2: Traffic Light Form 9 Appendix 3: Vision and Strategic Priorities Form 16 Appendix 4: Summary of Infrastructure Providers and Statutory Consultee Comments 20 Cheshire East Local Plan Strategy: Final Site Selection Report Alderley Park 1. Introduction 1.1 The ‘Cheshire East Local Plan Strategy: Site Selection Report – Alderley Park was published as background evidence to the Cheshire East Local Plan Strategy Proposed Changes Version (LPS) consultation, which took place from 4 March to 19 April 2016. The Report documented the implementation of the Site Selection Methodology (SSM) for Alderley Park. 1.2 This Report considers: (i) any additional information that has been submitted, in relation to the site and whether such information means that the conclusion and recommendation, using the SSM should change, in relation to the site; (ii) the responses, relating to the site, submitted to the public consultation in March/April 2016. 1.3 This Report supersedes the March 2016 Report; it makes it clear where circumstances have changed in relation to the site and makes recommendations accordingly, some of which may be different to those made in the March 2016 Report. 1.4 This Report should be read alongside the SSM report (and its associated evidential documents, including the Urban Potential Assessment (UPA) [PS E039b], and Edge of Settlement Assessment (ESA) [PS E039b]), the Sustainability Appraisal (SA)/Habitats Regulations Assessment (HRA), and the Cheshire East Council Proposed Changes to the Local Plan Strategy (Consultation Draft) February 2016.
    [Show full text]